WilmerHale Advises Beam Therapeutics on $500 Million Underwritten Offering

WilmerHale Advises Beam Therapeutics on $500 Million Underwritten Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On March 10, 2025, Beam Therapeutics Inc., a biotechnology company establishing the leading, fully integrated platform for precision genetic medicines, anchored by its proprietary base editing technology, announced the pricing of its underwritten registered direct offering of 16,151,686 shares of its common stock and pre-funded warrants to purchase 1,404,988 shares of its common stock. The aggregate gross proceeds to Beam were $500 million, before deducting underwriting discounts and commissions and other offering expenses payable by Beam. 

The WilmerHale team representing Beam consisted of Cynthia Mazareas, Molly Fox, Erin Bruynell Gallagher and Emily Ivers, with assistance from Meghan Walsh, Ben Kelsey, Simona Altshuler, Bruce Manheim, Tim Silva, Annaka Merrick, Heidi Treiber and Cindy Sullivan. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel